An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines

by Dionne, Francois, Aminkeng, Folefac, Bhavsar, Amit P, Groeneweg, Gabriella, Smith, Anne, Visscher, Henk, Rassekh, Shahrad Rod, Ross, Colin, Carleton, Bruce
Published 2022

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer

by Aminkeng, Folefac, Ross, Colin JD, Rassekh, Shahrad R, Rieder, Michael J, Bhavsar, Amit P, Sanatani, Shubhayan, Bernstein, Daniel, Hayden, Michael R, Amstutz, Ursula, Carleton, Bruce C
Published 2022

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity

by Aminkeng, Folefac, Ross, Colin JD, Rassekh, Shahrad R, Hwang, Soomi, Rieder, Michael J, Bhavsar, Amit P, Smith, Anne, Sanatani, Shubhayan, Gelmon, Karen A, Bernstein, Daniel, Hayden, Michael R, Amstutz, Ursula, Carleton, Bruce C
Published 2022

Genome-wide Scan Identifies Association Between an Interferon Regulatory Factor Variant and Interferon-beta Induced Liver Injury in Multiple Sclerosis Patients

by Kowalec, Kaarina, Wright, Galen EB, Drogemoller, Britt I, Aminkeng, Folefac, Bhavsar, Amit P, Kingwell, Elaine, Yoshida, Eric M, Traboulsee, Anthony, Marrie, Ruth Ann, Kremenchutzky, Marcelo, Campbell, Trudy L, Duquette, Pierre, Chalasani, Naga, Wadelius, Mia, Hallberg, Par, Xia, Zongqi, De Jager, Philip, Ross, Colin, Tremlett, Helen, Carleton, Bruce
Published 2022

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

by Aminkeng, Folefac, Bhavsar, Amit P, Visscher, Henk, Rassekh, Shahrad R, Li, Yuling, Lee, Jong W, Brunham, Liam R, Caron, Huib N, van Dalen, Elvira C, Kremer, Leontien C, van der Pal, Helena J, Amstutz, Ursula, Rieder, Michael J, Bernstein, Daniel, Carleton, Bruce C, Hayden, Michael R, Ross, Colin JD
Published 2022

Common variation near IRF6 is associated with IFN-beta-induced liver injury in multiple sclerosis

by Kowalec, Kaarina, Wright, Galen EB, Drogemoller, Britt I, Aminkeng, Folefac, Bhavsar, Amit P, Kingwell, Elaine, Yoshida, Eric M, Traboulsee, Anthony, Marrie, Ruth Ann, Kremenchutzky, Marcelo, Campbell, Trudy L, Duquette, Pierre, Chalasani, Naga, Wadelius, Mia, Hallberg, Par, Xia, Zongqi, De Jager, Philip L, Denny, Joshua C, Davis, Mary F, Ross, Colin JD, Tremlett, Helen, Carleton, Bruce C
Published 2022

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer

by Drogemoller, Britt I, Monzon, Jose G, Bhavsar, Amit P, Borrie, Adrienne E, Brooks, Beth, Wright, Galen EB, Liu, Geoffrey, Renouf, Daniel J, Kollmannsberger, Christian K, Bedard, Philippe L, Aminkeng, Folefac, Amstutz, Ursula, Hildebrand, Claudette A, Gunaretnam, Erandika P, Critchley, Carol, Chen, Zhuo, Brunham, Liam R, Hayden, Michael R, Ross, Colin JD, Gelmon, Karen A, Carleton, Bruce C
Published 2022

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines

by Drogemoller, Britt I, Wright, Galen EB, Shih, Joanne, Monzon, Jose G, Gelmon, Karen A, Ross, Colin JD, Amstutz, Ursula, Carleton, Bruce C, Chang, Wan C, Connolly, Mary B, Dionne, Francois, Groeneweg, Gabriella, Loucks, Catrina M, MacLeod, Stuart M, Pritchard, Sheila, Rassekh, Shahrad R, Sanatani, Shubhayan, Bhavsar, Amit P, Rieder, Michael J, Shear, Neil H, Ito, Shinya, Liu, Geoffrey, Khayat, Philip, Bernstein, Daniel, Lesko, Lawrence J, Aminkeng, Folefac
Published 2022